SingVaSC, Singapore Vascular Surgical Collaborative, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
SingVaSC, Singapore Vascular Surgical Collaborative, Singapore; Renal Transplantation and Vascular Access Surgery, Royal London Hospital, London, United Kingdom.
J Vasc Surg. 2018 Jul;68(1):285-297. doi: 10.1016/j.jvs.2018.03.428.
Long-term patency of arteriovenous fistulas (AVFs) is critical for hemodialysis vascular access. We compared the efficacy of a one-stage vs two-stage approach to brachiobasilic AVF creation by primarily investigating primary and secondary patency rates. We hypothesize that the two-stage is superior to the one-stage procedure in terms of efficacy and safety.
This review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Searches were performed on MEDLINE, EMBASE, Google Scholar, and Cochrane Database. Risk of bias and quality assessment scores were both performed based on previously validated tool.
The systematic search revealed a total of 242 publications for possible inclusion. On the basis of title and abstract review, two randomized controlled trials and nine case-cohort series fit our inclusion criteria. There were no statistically significant differences in failure rates (pooled risk ratio [RR], 1.10; 95% confidence interval [CI], 0.79-1.55; P = .25), 1-year primary patency rates (RR, 1.31; 95% CI, 0.83-2.06; P = .24), 1-year secondary patency rates (RR, 0.97; 95% CI, 0.54-1.77) and 2-year secondary patency rates (RR, 1.19; 95% CI, 0.54-2.63; P = .67) between both groups. However, the two-stage procedure had significantly improved 2-year primary patency rates (RR, 2.50; 95% CI, 1.66-3.74; P < .00001). There were no differences in steal syndrome, hematoma, infection, pseudoaneuryms, or stenosis, although there was a trend toward an increased incidence of postoperative thrombosis (RR, 1.81; 95% CI, 0.95-3.45; P = .07) in one-stage procedures.
With improved 2-year primary patency rates and the absence of significant differences in complications, this study suggests potential benefit of a two-stage over a one-stage procedure for brachiobasilic AVF creation. However, rather than being a definitive answer, our results merely highlight the continuing need for an adequately powered, well-designed, randomized controlled trial to interrogate this question further.
动静脉瘘(AVF)的长期通畅性对于血液透析血管通路至关重要。我们通过主要研究初次通畅率和次级通畅率比较了一期和两期法建立肱动脉-桡动脉内瘘的效果。我们假设两期法在疗效和安全性方面优于一期法。
本综述按照系统评价和荟萃分析的首选报告项目进行。在 MEDLINE、EMBASE、Google Scholar 和 Cochrane 数据库中进行了检索。根据先前验证的工具进行了偏倚风险和质量评估评分。
系统检索共显示出 242 篇可能纳入的文献。根据标题和摘要审查,两项随机对照试验和九项病例队列研究符合我们的纳入标准。失败率无统计学差异(合并风险比 [RR],1.10;95%置信区间 [CI],0.79-1.55;P =.25),1 年初次通畅率(RR,1.31;95%CI,0.83-2.06;P =.24),1 年次级通畅率(RR,0.97;95%CI,0.54-1.77)和 2 年次级通畅率(RR,1.19;95%CI,0.54-2.63;P =.67)在两组之间无统计学差异。然而,两期法显著提高了 2 年的初次通畅率(RR,2.50;95%CI,1.66-3.74;P<0.00001)。两组之间在窃血综合征、血肿、感染、假性动脉瘤或狭窄方面无差异,但一期手术中术后血栓形成的发生率有增加的趋势(RR,1.81;95%CI,0.95-3.45;P =.07)。
由于 2 年的初次通畅率提高,且并发症无显著差异,本研究表明肱动脉-桡动脉内瘘建立两期法优于一期法。然而,我们的结果仅仅突出了需要进一步研究的问题,这并不是一个明确的答案,而是需要进行一项设计合理、随机对照试验。